TLR7 and melanoma: Our previous study demonstrated that stimulation with a TLR7 agonist enhances anticancer effects via autophagic cell death during radiotherapy for melanoma, suggesting that TLR7 agonists can induce autophagic cell death (Cho et al., 2017).